.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Imetelstat (RYTELO (TM)), an oligonucleotide telomerase inhibitor, is being developed by Geron Corporation for the treatment of myeloid hematologic malignancies. In June 2024, imetelstat was approved in the USA for use in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). This article summarizes the milestones in the development of imetelstat leading to this first approval for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.
Keyword:
TELOMERASE INHIBITOR
OLIGONUCLEOTIDE
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Characterization of polymeric insulators using thermal and UV imaging under laboratory conditions.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms世界卫生组织第5版血淋巴肿瘤分类: 骨髓和组织细胞/树突状肿瘤.png)
LEUKEMIA
OAAI
LEUKEMIAIF13.4
OAAI分享收藏Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebocontrolled, phase 3 trialLANCET
LANCETIF88.5
PREAI
分享收藏
查看更多内容